Publication Topic

Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680. PMID: 38991779.

Burnett J, Sychterz C, Zhu D, Shakeel F, Dingley K, Chen W, et al. Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug interaction (DDI) study: Case study of mezigdomide. Poster presented at American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Colorado Springs, CO, March 2024.

Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K, Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.

Robison TW. How many doses of an Ames-positive/mutagenic (DNA reactive) drug can be safely administered to healthy subjects? Genetic Toxicology Association, 2021.

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

Robison TW. Regulatory review of XELJANZ® (Tofacitinib) from the nonclinical perspective. American College of Toxicology Annual Meeting, 2013.

Urban JD, Vargas G, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacol 32(1):67-77; doi: 10.1038/sj.npp.1301071.

Urban JD, Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

Thompson CM, Kawashima H, and Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 359(1):115–121; doi: 10.1006/abbi.1998.0892.

Choksi NY, Hussain A, Owens CE, Myers AM, Harvey RD, Baldessarini RJ, Wyrick SD, Booth RG. Adenosine A2 and PAT- σ3 agonists affect adenylyl cyclase activity and dopamine synthesis. Poster presented at North Carolina Society for Neuroscience Meeting, 1994.